Seismic Pharmaceuticals starts global Phase 3 trial of Istaroxime in cardiogenic shock
AI Summary- Seismic Pharmaceuticals began the Rescue HF CS Phase 3 trial of Istaroxime in cardiogenic shock.
- Approximately 600 patients will be enrolled across sites in the United States, Europe and South America.
- More than 340 patients received Istaroxime in four completed Phase 2 trials.